Pharmaceutical Executive

Pharmaceutical Executive Daily: FDA Approves First and Only Oral Film Treatment for Erectile Dysfunction

05 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical protocols should be trea...

Pharmaceutical Executive Daily: Susan G. Komen Releases Breast Cancer Outlook for 2026

04 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders explore how pharma can ...

Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech

03 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous ind...

Pharmaceutical Executive Daily: FDA Reveals PreCheck Pilot Program

02 Feb 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA introduces a PreCheck pilot program aimed at strengthening domestic manufacturing oversight, an A...

Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements

30 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving Pfizer and Eli Lilly, HHS re...

Pharmaceutical Executive Daily: The Disconnect Between Pharma and MedTech

29 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still struggle to deliver truly ...

Pharmaceutical Executive Daily: Eli Lilly Enters $1 Billion Research Collaboration with Seamless Therapeutics

28 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardi...

Pharmaceutical Executive Daily: Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist

27 Jan 2026

Contributed by Lukas

In today’s pharmaceutical executive daily, Roche reports positive Phase II results for a dual GLP-1/GIP receptor agonist, procurement leaders reasse...

Pharmaceutical Executive Daily: Mirum Pharmaceuticals Acquires Bluejay Therapeutics

26 Jan 2026

Contributed by Lukas

In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million acquisition, industry ex...

Pharmaceutical Executive Daily: Tariff Uncertainty Accelerates Manufacturing Shifts

23 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, tariff uncertainty triggers a short-term surge in pharmaceutical manufacturing activity, workforce burnou...

Pharmaceutical Executive Daily: United States' Set to Exit WHO

22 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the World Health Organization finalizes the United States’ withdrawal from the global health body, Bris...

Pharmaceutical Executive Daily: New Study Finds No Evidence Linking Tylenol Use to Autism Risk

21 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, a new study reignites debate over a potential link between Tylenol use and autism risk, TopGum signs a $1...

Pharmaceutical Executive Daily: GSK's $2 Billion Acquisition of RAPT Therapeutics

20 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of RAPT Therapeutics, Atkin...

Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma

19 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class a...

Pharmaceutical Executive Daily: President Trump's Great Healthcare Plan

16 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Johnson & Johnson announces plans for a second $2 billion manufacturing facility in North Carolina, Presi...

Pharmaceutical Executive Daily: Continued Coverage of the 2026 J.P. Morgan Healthcare Conference

15 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Genmab outlining a disciplined st...

Pharmaceutical Executive Daily: 2026 J.P. Morgan Healthcare Conference Coverage

14 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily we will focus on the 44th Annual J.P. Morgan Healthcare Conference, with Biogen outlining how a more focus...

Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment

12 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Johnson & Johnson reaches an agreement with the Trump administration while continuing its $55 billion U.S...

Pharmaceutical Executive Daily: FDA Limits Regulations of Non-Medical Fitness Devices

08 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry leaders examine how humans a...

Pharmaceutical Executive Daily: Amgen Acquires Dark Blue Therapeutics for $840 Million

07 Jan 2026

Contributed by Lukas

Pharmaceutical Executive Daily: Alnylam Invests $250 Million in Manufacturing Facility

06 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly and Nimbus Therapeutics announce a major licensing deal for oral obesity treatments, Hoth Thera...

Pharmaceutical Executive Daily: Wegovy Pill Becomes Available

05 Jan 2026

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, clears a new therapy to pre...

Pharmaceutical Executive Daily: FDA Approves Wegovy Pill

23 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears Roche’s Lunsumio Ve...

Pharmaceutical Executive Daily: Nine New Additions to TrumpRx

22 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, AstraZeneca reaches a $2 b...

Scaling Sustainability: A Big Pharma Formula

22 Dec 2025

Contributed by Lukas

In this enlightening conversation with Pharm Exec, Jim Greffet, VP of sustainability at Eli Lilly, unpacks how environmental, social, and governance (...

Pharmaceutical Executive Daily: US Senate Passes Biosecure Act

19 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly announces positive topline Phase III data for its oral GLP-1 candidate orforglipron, the U.S. S...

Pharmaceutical Executive Daily: Pfizer's Stock Drops Following 2026 Revenue Projections Release

18 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House Republicans moves to force a ...

Pharmaceutical Executive Daily: FDA's Approval of Lerochol

17 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals spanning Alzheimer’s ...

Pharmaceutical Executive Daily: TrumpRx's Critical Blind Spot

16 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a national priority voucher ...

Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results

15 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna l...

Pharmaceutical Executive Daily: FDA's Approval of Waskyra

11 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for...

Pharmaceutical Executive Daily: FDA's New Standard for CAR-T Approvals

10 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA introduces a new superiority standard for future CAR-T approvals, Relation Therapeutics and Novar...

Pharmaceutical Executive Daily: Carvykti Demonstrates Sustained Remissions

09 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, new analysis outlines how EMA support programs help lower drug market entry costs, early real-world data ...

Pharmaceutical Executive Daily: FDA Approves Breyanzi

08 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met its primary endpoint in a...

Pharmaceutical Executive Daily: Mark Cuban's Push for Generic Drug Fee Waivers

05 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, former FDA commissioners caution that new vaccine policies could weaken long-established regulatory stand...

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

04 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, the FDA appoints Tracy Beth Høeg as acting CDER director, health systems explore new commercialization ...

Pharmaceutical Executive Daily: FDA's Agentic AI Deployment

03 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Regeneron launches a $150 million gene editing collaboration with Tessera Therapeutics, the FDA begins ag...

Pharmaceutical Executive Daily: Lilly Reduces the Price of Zepbound

02 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Eli Lilly reduces the price of Zepbound single-dose vials for self-pay patients, a new report claims the ...

Pharmaceutical Executive Daily: U.S. & U.K. Agree to 0% Tariffs on Pharmaceutical Products

01 Dec 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Novo Nordisk files for FDA approval of a higher-dose Wegovy injectable using a priority review voucher, t...

Pharmaceutical Executive Daily: Novartis Cuts 550 Jobs

26 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Novartis plans to eliminate 550 positions at a major Swiss site, the FDA authorizes the first gene therap...

Pharmaceutical Executive Daily: Moderna's $1.5 Billion Loan

25 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Novo Nordisk faces market pressure after a late-stage trial setback, Moderna takes out a $1.5 billion loa...

Pharmaceutical Executive Daily: Tesaro and AnaptysBio's Legal Battle

24 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, learn how Tesaro is suing AnaptysBio over alleged contract breaches, Flagship Pioneering and Valo Health ...

Pharmaceutical Executive Daily: Novartis' North Carolina Manufacturing Hub

21 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, learn how Abbott is acquiring Exact Sciences in a major diagnostics deal, Novartis is building a new manu...

Pharmaceutical Executive Daily: Moderna's $140 Million Manufacturing Investment

20 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, learn how Moderna is expanding its manufacturing footprint in Massachusetts, GSK is advancing new researc...

Pharmaceutical Executive Daily: FDA's Approval of Epkinly

19 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, learn how Novo Nordisk is launching an introductory offer for Wegovy and Ozempic, AbbVie and Genmab gain ...

Pharmaceutical Executive Daily: Novo Nordisk's Leadership Restructure

18 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio...

Pharmaceutical Executive Daily: WeightWatchers Planning to Offer Wegovy Following Approval

13 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA unveils a new Plausi...

Pharmaceutical Executive Daily: Dr. Richard Pazdur Appointed as Director CDER

13 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, Richard Pazdur is named director of FDA’s Center for Drug Evaluation and Research, Pfizer strengthens f...

Pharmaceutical Executive Daily: AstraZeneca Becomes UK's Largest Stock

12 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, AstraZeneca surpasses Shell to become the UK’s largest listed company, Basel intensifies efforts to att...

Pharmaceutical Executive Daily: Wegovy Shows Potential to Treat MASH Patients

11 Nov 2025

Contributed by Lukas

Raising Biomarker Awareness

10 Nov 2025

Contributed by Lukas

Dr. Jaspal Singh explains some of the barriers that prevent cancer patients from getting biomarker testing early in their treatment journey.

Pharmaceutical Executive Daily: FDA Approves Darzalex Faspro

10 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Darzalex Faspro for adults with high-risk smoldering multiple myeloma, t...

Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1's to TrumpRX

07 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Eli Lilly and Novo Nordisk’s plans to bring their leading weight-loss medications to the Trump...

Pharmaceutical Executive Daily: Novo Nordisk's Amended Acquisition Proposal

06 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Ken...

Pharmaceutical Executive Daily: Kimberly-Clark’s $48.7 Billion Acquisition of Kenvue

05 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 billion investment to str...

Pharmaceutical Executive Daily: Pfizer Files Lawsuits Against Metsera and Novo Nordisk

04 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged intellectual property infringe...

Pharmaceutical Executive Daily: George Tidmarsh Resigns from FDA

03 Nov 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Eli Lilly’s plan to submit its oral GLP-1 candidate for FDA priority review, the departure of ...

Pharmaceutical Executive Daily: Novo Nordisk's Unsolicited Acquisition Proposal

31 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’...

Pharmaceutical Executive Daily: Thermo Fisher's $8.8 Billion Acquisition of Clario Holdings

30 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Thermo Fisher’s $8 billion agreement to acquire Clario Holdings, Eli Lilly’s partnership wit...

Pharmaceutical Executive Daily: Lilly and NVIDIA Create AI Supercomputer

29 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Eli Lilly’s partnership with NVIDIA to develop an AI supercomputer for drug discovery, a surge...

Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns

28 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover the resignation of Organon CEO Kevin Ali following an internal investigation tied to Nexplanon s...

Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age

27 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover the FDA approval of Bayer’s Lynkuet for menopausal hot flashes, new research suggesting Ozempi...

Pharmaceutical Executive Daily: TrumpRx's Implication on DTC Commercialization

24 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover the emergence of TrumpRx and its implications for direct-to-consumer drug commercialization, new...

Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up

23 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover market reaction to Novo Nordisk’s recent board shake-up, MJH Life Sciences’ acquisition of B...

Pharmaceutical Executive Daily: Novo Nordisk's Board Shake-Up

22 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to reject a petition ca...

Pharmaceutical Executive Daily: Merck's $70 Billion Investment

21 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Merck’s $70 billion expansion of U.S. operations, the FDA’s latest approvals for Novo Nordis...

Pharmaceutical Executive Daily: FDA's National Priority Voucher Program

20 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover the FDA’s creation of a new National Priority Voucher Program, the market reaction to Presiden...

Shifting Focus in Autoimmune Diseases

20 Oct 2025

Contributed by Lukas

Artax Biopharma’s CEO Rob Armstrong explains recent shifts in autoimmune R&D before discussing his leadership style.

Pharmaceutical Executive Daily: EMD Serono’s Agreement with US Government

17 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we explore how antibody-drug conjugate collaborations are moving beyond oncology into autoimmune diseases...

Pharmaceutical Executive Daily: Rethinking Workforce Development

16 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we explore how pharma leaders are rethinking workforce development at the executive level, the industry’...

Pharmaceutical Executive Daily: Johnson & Johnson Separating Its Orthopedics Unit

15 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopaedics division into a standalone company, th...

Pharmaceutical Executive Daily: Direct-To-Consumer Trends

14 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff and pricing pressure...

Advancing Neuroscience and Rare Disease Innovation

14 Oct 2025

Contributed by Lukas

Acadia Pharmaceuticals’ CEO Catherine Owen Adams discusses the current climate in R&D and details her leadership style.

Pharmaceutical Executive Daily: Policy Whiplash

13 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Ypsomed’s new North Carolina manufacturing site, how pharma leaders are maintaining strategic ...

Pharmaceutical Executive Daily: Most Favored Nation Order's Evolving Landscape

10 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ongoing legal and mar...

Pharmaceutical Executive Daily: Why DSCSA Compliance is Only The Beginning

09 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Johnson & Johnson’s Simponi for pediatric ulcerative colitis, why DSCS...

Pharmaceutical Executive Daily: Amgen Launches New Direct-To-Consumer Platform

08 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we explore why medical AI success depends on more than algorithms, Amgen’s launch of its new direct-to-...

Pharmaceutical Executive Daily: FDA Lifts Clinical Hold on NUZ-001

07 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover the FDA lifting its clinical hold on Neurizon Therapeutics’ lead program Nuz-001, the agency’...

Pharmaceutical Executive Daily: Updated Vaccine Recommendations

06 Oct 2025

Contributed by Lukas

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today’s Pha...

Pharmaceutical Executive Daily: FDA's new Fast-Track Review

03 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover the FDA’s new fast-track review program for U.S.-made generics, Novartis’ FDA approval of Rh...

Pharmaceutical Executive Daily: President Trump Pauses Tariff Plan

02 Oct 2025

Contributed by Lukas

Stay informed on key pharmaceutical news, including tariff updates, FDA shutdown risks, and insights from recent cell and gene therapy reviews.

Pharmaceutical Executive Daily: Novo Nordisk Resubmits BLA for Awiqli

01 Oct 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s resubmission of its BLA for Awiqli, the FDA’s approval of Kedrion’s Qivigy ...

Pharmaceutical Executive Daily: September 30, 2025

30 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover AbbVie’s new API manufacturing site in Illinois, AstraZeneca’s plan to harmonize its global ...

Pharmaceutical Executive Daily: September 29, 2025

29 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s appointment of Luke Miels...

Pharmaceutical Executive Daily: September 26, 2025

26 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover the White House’s push for a Most Favored Nation drug pricing model, the FDA’s approval of E...

Pharmaceutical Executive Daily: September 25, 2025

25 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Glenmark’s billion-dollar exclusive licensing deal with Hengrui, Harmony Biosciences’ trial ...

Pharmaceutical Executive Daily: September 24, 2025

24 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover the market reaction to Trump’s Tylenol–autism claim, the FDA’s complete response letter to...

Pharmaceutical Executive Daily: September 23, 2025

23 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover GSK’s supplemental application to update the label for Leucovorin, the FDA’s complete respon...

Pharmaceutical Executive Daily: September 22, 2025

22 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Biogen’s acquisition of Alcyone Therapeutics to expand its drug delivery solutions, the FDA’...

Pharmaceutical Executive Daily: September 19, 2025

19 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover how pharma companies can scale AI pilots into enterprise-wide value, GSK’s plan to invest $30 ...

Pharmaceutical Executive Daily: September 18, 2025

18 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we explore how AI is disrupting higher education and career pathways, AllRock Bio’s $50 million Series ...

Pharmaceutical Executive Daily: September 17, 2025

17 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, Merck and Daiichi Sanky...

Pharmaceutical Executive Daily: September 16, 2025

16 Sep 2025

Contributed by Lukas

Pharmaceutical Executive Daily: September 15, 2025

15 Sep 2025

Contributed by Lukas

Pharmaceutical Executive Daily: September 12, 2025

12 Sep 2025

Contributed by Lukas

Today's episode covers the president’s call to lower drug costs for patients, the compliance and operational pressures facing pharmaceutical manufac...

Pharmaceutical Executive Daily: September 11, 2025

11 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover Lundbeck’s restructuring affecting more than 600 international employees, Novo Nordisk’s glo...

Pharmaceutical Executive Daily: September 9, 2025

09 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we explore strategies to strengthen pharma sales messaging, the role of AI-driven simulations in field re...

Pharmaceutical Executive Daily: September 8, 2025

08 Sep 2025

Contributed by Lukas

Pharmaceutical Executive Daily: September 5, 2025

05 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we will recap the top stories of the week, exploring the current state of the GLP-1 market, review major ...

Pharmaceutical Executive Daily: September 4, 2025

04 Sep 2025

Contributed by Lukas

In today’s Pharmaceutical Executive Daily, we cover political pressure on Moderna and Novavax to release COVID-19 vaccine evidence, a deep dive into...